Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence
of red and silver scaly plaques. About 30% of psoriasis sufferers develop psoriatic arthritis …

Apremilast (Otezla®) is an orally administered, small molecule inhibitor of
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …

Psoriasis is a chronic immune-mediated disease associated with several co-morbidities and
negative impacts on a patient's quality of life. Despite the advances in biologic therapy, there …

Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a
prolonged and safe control of the disease is needed. Current anti-psoriatic treatments show …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4).
Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and …

Several classes of new oral therapy are in use or in development for the treatment of
psoriasis. Despite the high efficacy of biologics, new oral therapies remain important as …

Apremilast (Otezla®) is an oral phosphodiesterase 4 inhibitor indicated for the twice-daily
treatment of adults with psoriasis and psoriatic arthritis (PsA). Its use in these patient …

ABSTRACT Introduction: Psoriasis (PSo) is a chronic inflammatory skin disease associated
with co-morbidities such as hypertension, diabetes, dyslipidemia and metabolic syndrome. It …